Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




STAT3 Linked to Interferon-Induced Antiviral Response

By LabMedica International staff writers
Posted on 09 Feb 2017
A recent paper reported the discovery of a previously unknown anti-viral role for the STAT3 (signal transducer and activator of transcription 3) protein, which links it to the interferon-alpha (IFN-alpha) immune signaling pathway.

Interferon (IFN)-alpha induces a wide spectrum of anti-viral mediators, via the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. More...
STAT1 and STAT2 have been well characterized and shown to upregulate IFN-stimulated gene (ISG) expression; but while STAT3 is also activated by IFN-alpha, its role in anti-viral ISG induction is unclear.

STAT3 is a member of the STAT protein family, which regulates many aspects of cell growth, survival, and differentiation. Malfunction of this signaling pathway is frequently observed in primary tumors and leads to increased angiogenesis and enhanced tumor survival. Knockout studies have provided evidence that STAT proteins are involved in the development and function of the immune system and play a role in maintaining immune tolerance and tumor surveillance. Constitutive STAT3 activation is associated with various human cancers and commonly suggests poor prognosis. It has anti-apoptotic as well as proliferative effects. Several viruses, including hepatitis C and mumps, reduce cellular STAT3 protein levels, via the promotion of ubiquitin-mediated proteasomal degradation. This viral immune evasion mechanism suggests an undiscovered anti-viral role for STAT3 in IFN-alpha signaling.

To investigate STAT3’s functional involvement in the Type I IFN pathway, investigators at Trinity College Dublin first analyzed its effect on the replication of two viruses, influenza and vaccinia. Viral plaque assays, using mouse wild type embryonic fibroblasts (MEFs) and MEFs that lacked STAT3, revealed that STAT3 was required for the inhibition of influenza and vaccinia replication. Furthermore, blocking STAT3 by short hairpin RNA (shRNA) inhibition also enhanced influenza replication and hindered induction of several, well characterized, anti-viral ISGs.

Senior author Dr. Nigel Stevenson, assistant professor of immunology at Trinity College Dublin, said, "For decades we have known that STAT3 is essential for healthy cell growth, but our new revelation identifies it for the first time as an essential anti-viral component in the interferon signaling pathway. In fact, we found that without STAT3, cells cannot fight the common flu virus or the pox vaccinia virus. We thought that since the interferon signaling pathway enhances the immune response against viruses so effectively, viruses might have evolved means to block it - such a reality would explain why several viruses are so troublesome to defeat."

"Of course a major goal of our ongoing work is to find solutions to the real-world problems faced by the thousands of people who cannot clear certain viruses after they have been infected," said Dr. Stevenson. "This discovery opens the door to new therapeutic options, which, we hope, will be able to help people restore their natural immunity against a host of problematic viruses."

The study was published in the December 17, 2016, online edition of the journal Cellular and Molecular Life Sciences.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.